DIM
CRL icon

DC Investments Management’s Charles River Laboratories CRL Stock Holding History

DC Investments Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-3,142
Closed -$344K – 271
2017
Q4 		$344K Buy
+3,142
New +$342K 0.14% 190

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

DC Investments Management's CRL Position: Q1 2018 in Review

DC Investments Management sold out of Charles River Laboratories (CRL) in Q1 2018, closing a stake of 3,142 shares — an estimated $344K sold.

DC Investments Management first reported a position in CRL in Q4 2017 and held it in 1 quarter. The position peaked at $344K in Q4 2017. 333 funds tracked by Wall St. Rank hold CRL as of Q1 2018.

  • DC Investments Management reported no remaining Charles River Laboratories position as of Q1 2018 after selling out during the quarter.
  • DC Investments Management sold 3,142 Charles River Laboratories shares in Q1 2018, an estimated $344K.
  • DC Investments Management first reported a position in Charles River Laboratories in Q4 2017 and held it in 1 quarter.
  • DC Investments Management's Charles River Laboratories position peaked at $344K in Q4 2017.
  • 333 funds tracked by Wall St. Rank held Charles River Laboratories as of Q1 2018.

Based on DC Investments Management's 13F filing for Q1 2018, filed 2 May 2018.